- Johnson & Johnson MedTech sponsors a new HRS data platform for PFA procedures.
- The registry aims to evaluate clinical outcomes and inform treatment strategies.
- Johnson & Johnson MedTech focuses on advancing PFA and arrhythmia care.
Introduction
Johnson & Johnson MedTech has announced its sponsorship of a new data collection platform developed by the Heart Rhythm Society (HRS). This platform is designed to capture real-world data on pulsed field ablation (PFA) procedures used to treat atrial fibrillation (AFib).
Registry Objectives
The registry aims to serve as a long-term data collection platform to evaluate clinical outcomes, support evidence-based practice, and inform the evolution of treatment strategies in electrophysiology.
Company Commitment
Johnson & Johnson MedTech is committed to advancing the science of PFA and driving progress in arrhythmia care. This is part of their broader effort to enhance healthcare through rigorous scientific inquiry and clinical excellence in electrophysiology.
Technological Integration
The company offers a comprehensive portfolio of imaging, mapping, and ablation technologies, including versatile PFA platforms, designed to deliver safe, precise, and consistent outcomes across a wide range of patient needs.
